These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23121619)

  • 21. Management of early stage chronic myeloid leukemia: state-of-the-art approach and future perspectives.
    Galaverna F; Ghiggi C; Guolo F; Beltrami G; Dellepiane C; Giannoni L; Carella A; Carella AM
    Curr Cancer Drug Targets; 2013 Sep; 13(7):749-54. PubMed ID: 23952099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
    Lee H; Basso IN; Kim DDH
    Int J Hematol; 2021 May; 113(5):632-641. PubMed ID: 33772728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Molecular biology and treatment of CML].
    Kimura S
    Rinsho Ketsueki; 2017; 58(10):1920-1930. PubMed ID: 28978834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.
    Breccia M; Foà R
    Curr Oncol Rep; 2018 Mar; 20(3):23. PubMed ID: 29511948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
    Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
    Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic myelogenous leukemia: biology and therapy.
    Gale RP; Grosveld G; Canaani E; Goldman JM
    Leukemia; 1993 Apr; 7(4):653-8. PubMed ID: 8464245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chronic myeloid leukemia: state-of-the-art management].
    Takahashi N
    Rinsho Ketsueki; 2018; 59(6):747-754. PubMed ID: 29973455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
    Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New drugs for chronic myelogenous leukemia.
    Santos FP; Quintás-Cardama A
    Curr Hematol Malig Rep; 2011 Jun; 6(2):96-103. PubMed ID: 21327563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent progress in the management of pediatric chronic myeloid leukemia.
    Shima H; Shimada H
    Int J Hematol; 2023 Feb; 117(2):182-187. PubMed ID: 36574169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
    Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
    Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
    [No Abstract]   [Full Text] [Related]  

  • 37. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
    Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
    Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.
    Shah NP
    J Natl Compr Canc Netw; 2019 May; 17(5.5):611-613. PubMed ID: 31117031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.
    Bisen A; Claxton DF
    Adv Exp Med Biol; 2013; 779():179-96. PubMed ID: 23288640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S; Tremblay D; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.